| Date | March 8, 2021 – present |
|---|---|
| Time | (GMT +2) |
| Location | Botswana |
| Cause | COVID-19 pandemic |
| Target | COVID-19 |
| Budget | $10 Million |
| Organised by | Ministry of Health and Wellness |
| Participants | 150,019 total doses administered (7 June 2021)
|
| Website | Registration Portal |
COVID-19 vaccination in Botswana is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.[ citation needed ]
Mass vaccination started on 26 March 2021, initially with AstraZeneca's Covishield vaccine. [1] As of 7 June 2021, Botswana has administered 150,019 doses. [2] [3]
| Vaccine name | Quantity | Doses Arrived | Approval |
|---|---|---|---|
| Pfizer-BioNTech | 101,790 | 101,790 |  Approved |
| CoronaVac | TBA | 200,000 | Approved |
| Covaxin | 166,600 | 66,600 | Approved |
| Janssen | 1,200,000 | 0 | Approved |
| Moderna | 500,000 | 0 | Approved |
| Oxford-AstraZeneca [4] | 38,400 | 38,400 | Approved |
In February, Botswana spent 10 million dollars on purchasing vaccines. [5]
Start of vaccinations of those aged 55 and older (phase 1) on 26 March, initially with 30,000 doses of Covishield donated by India and 33,600 doses purchased through the COVAX facility. [6] [7] [8]
In the first four weeks 47,160 persons received their first inoculation. [9] A week later, on 30 April, the number of vaccinated persons had increased to 49,882. [10] [11]
49,959 persons had received their first inoculation by 3 May; 53,375 by 7 May; and 142,864 by 28 May. [12]
On 29 May Botswana received 38,400 doses of the Oxford-AstraZeneca vaccine through COVAX, facilitated by UNICEF Botswana. [13] [14]
On 3 June Botswana received 19,890 doses of the Pfizer-BioNTech vaccine through COVAX. A supply agreement with Moderna was announced. [12] [15] [ better source needed ] [16]
On 24 June Botswana received 200,000 doses of the CoronaVac vaccine. [17] By the end of the month 91,482 persons had been fully vaccinated.
Vaccination of 55-year-olds and older resumed on 5 July. Health ministry officials announced their intention to extend vaccination to those aged 30 to 54 (phase 2) at the end of July. [17]
On 16 July, the Ministry of Health and Wellness reported a shortfall of 15,000 doses of the Oxford-AstraZeneca vaccine, initially foreseen for delivery in early June. To remedy the shortfall and ensure that those already vaccinated once with Oxford-AstraZeneca received their second inoculation within 12 weeks of the first, the Ministry recommended using the Moderna or Pfizer-BioNTech vaccines for the second dose in case Oxford-AstraZeneca was unavailable. [18]
On 30 July, the Minister for Health and Wellness informed that out of more than two million vaccine doses on order, only 282,890 doses had been delivered so far. [19] By the end of the month 127,362 persons had been fully vaccinated.
In August, the chief executive officer of former president Ian Khama's SKI Khama Foundation issued a statement to the effect that the foundation had secured two million doses of the Oxford-AstraZeneca vaccine and two million doses of the Pfizer-BioNTech vaccine, sourced through U.S. firm KKM Global Group. The foundation offered the government to purchase the four million doses but needed a decision within five business days. Pfizer and AstraZeneca denied supplying any doses to KKM Global Group. [20] [21]
On 8 August, Botswana received 38,400 doses of the Oxford-AstraZeneca vaccine, followed by 108,000 doses of the Janssen vaccine. [22] On 19 August, it received 81,900 doses of the Pfizer-BioNTech vaccine donated by the United States. [23]
By 23 August, Greater Gaborone had run out of Oxford-AstraZeneca, Janssen and CoronaVac doses and had to halt first inoculations until further notice, pending the arrival of more vaccine doses. Inoculations resumed a month later.
By the end of the month, 337,989 persons had received their first inoculation and 215,502 had received both doses.
On 5 September, Botswana received 404,494 doses of the CoronaVac vaccine. [24]
On 18 September, Botswana received the first 101,760 of 401,280 Oxford-AstraZeneca doses donated by Germany. [25]
On 23 September, Botswana received 50,400 doses of the Janssen vaccine donated by South Africa.
By the end of the month 245,559 persons had been fully vaccinated.
On 14 October, Botswana received a first batch of 49,200 doses under the supply agreement with Moderna reached in June 2021. One week later, it received 72,000 doses of the Janssen vaccine purchased through the African Vaccine Acquisition Trust, followed by 72,000 more doses of the same vaccine on 25 October and 57,600 doses on 30 October.
By the end of the month 383,320 persons had been fully vaccinated, corresponding to 40% of the targeted population.
On 18 November, Botswana received 100,260 doses of the Pfizer-BioNTech vaccine through COVAX.
By the end of the month 519,544 persons had been fully vaccinated, corresponding to 93% of the targeted population.
Botswana received 525,230 doses of the Pfizer-BioNTech vaccine on 2 December; 200,070 doses of the same vaccine on 6 December; 151,200 and 79,200 of the Janssen vaccine on 6 and 8 December respectively. On 12 December it received 72,000 doses of the Janssen vaccine and 72,000 Oxford-AstraZeneca doses, followed by 737,100 doses of the Pfizer-BioNTech vaccine on 16 December.
By the end of the month 1.03 million persons had been fully vaccinated, exceeding the targeted population.
By the end of the month more than 1.1 million persons had been fully vaccinated, exceeding the targeted population.
By the end of the month more than 1.4 million persons had been fully vaccinated, exceeding the targeted population.
By the end of the month more than 1.9 million persons had been fully vaccinated, exceeding the targeted population.
Cumulative vaccinations
 | Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org. |
COVID-19 Vaccines Global Access, abbreviated as COVAX, is a worldwide initiative aimed at equitable access to COVID-19 vaccines directed by the GAVI vaccine alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the World Health Organization (WHO), alongside key delivery partner UNICEF. It is one of the four pillars of the Access to COVID-19 Tools Accelerator, an initiative begun in April 2020 by the WHO, the European Commission, and the government of France as a response to the COVID-19 pandemic. COVAX coordinates international resources to enable low-to-middle-income countries equitable access to COVID-19 tests, therapies, and vaccines. UNICEF is the key delivery partner, leveraging its experience as the largest single vaccine buyer in the world and working on the procurement of COVID-19 vaccine doses, as well as logistics, country readiness and in-country delivery.
The COVID-19 vaccination program in the Philippines was a mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a day after the arrival of the country's first vaccine doses which were donated by the Chinese government.
The COVID-19 vaccination campaign in Italy is a mass immunization campaign that was put in place by the Italian government in order to respond to the ongoing COVID-19 pandemic. It started on 27 December 2020, together with most countries in the European Union.
The general COVID-19 vaccination in Australia program began on 22 February 2021 in response to the COVID-19 pandemic, with the goal of vaccinating all willing people in Australia before 2022. Front-line workers and aged care staff and residents had priority for being inoculated, before a gradual phased release to less-vulnerable and lower-risk population groups throughout 2021. The Therapeutic Goods Administration (TGA) approved four vaccines for Australian use in 2021: the Pfizer–BioNTech vaccine on 25 January, the Oxford–AstraZeneca vaccine on 16 February, Janssen vaccine on 25 June and the Moderna vaccine on 9 August. Although approved for use, the Janssen vaccine was not included in the Australian vaccination program as of June 2021.
COVID-19 vaccination in South Africa is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Angola is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country. As of 15 June 2021, Angola has administered 1,314,375 doses of vaccines.822,109 people with the first dose and 492,266 people fully vaccinated. Angola began their vaccination program shortly after receiving their first shipment of Oxford AstraZeneca vaccine in early March 2021.
Cape Verde has begun vaccinations against COVID-19.
The COVID-19 vaccination program in Colombia is an ongoing effort of mass immunization put in place by the Colombian government in order to respond to the ongoing COVID-19 pandemic. The virus causing COVID-19 was confirmed to have reached Colombia on 6 March 2020. Colombia's preparation and readiness for a vaccine program allowed it to join the first group of countries who received vaccines through COVAX. The first vaccine in Colombia was given to a nurse on 17 February 2021.
COVID-19 vaccination programs are ongoing in the majority countries and territories in Africa, with 51 of 54 African countries having launched vaccination programs by July 2021. As of October 2023, 51.8% of the continent's population is fully vaccinated with over 1084.5 million doses administered.
The COVID-19 vaccination in Vietnam is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country. Following the approval of the Oxford–AstraZeneca COVID-19 vaccine on 30 January 2021, vaccinations commenced on 8 March 2021, and will continue throughout the year with the goal of vaccinating 80% of the population by June 2022. The Sputnik V was later approved for use on 23 March 2021. The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, 29 June 2021, and 15 July 2021, respectively. Vietnam approved Abdala vaccine from Center for Genetic Engineering and Biotechnology on 18 September 2021, and Covaxin from Bharat Biotech on 10 November 2021.
The COVID-19 vaccination in Indonesia is an ongoing mass immunization in response to the COVID-19 pandemic in Indonesia. On 13 January 2021, the program commenced when President Joko Widodo was vaccinated at the presidential palace. In terms of total doses given, Indonesia ranks third in Asia and fifth in the world.
Bangladesh began the administration of COVID-19 vaccines on 27 January 2021 while mass vaccination started on 7 February 2021.
Nepal began administration of COVID-19 vaccines on 27 January 2021. 1 million Oxford-Astrazeneca vaccines were provided by India as a grant while Nepal brought 2 million doses from Serum Institute of India (SII) and was one of the first to receive COVID-19 vaccines. The delivery of the first 1 million doses arrived on 21 February. In March, India's decision to ban exports of vaccines created uncertainty over whether Nepal would be able to continue its vaccinations. By April, SII had only provided half of the 2 million doses for which Nepal had paid in full. A spokesperson for the Indian Ministry of External Affairs rejected the notion of an export ban and said "We will export vaccines taking into account the domestic demand." By late July, there was still uncertainty in Nepal over when SII would deliver the vaccines that were purchased, although Prime Minister Narendra Modi said India would "resume the supply of vaccines soon."
COVID-19 vaccination in Iceland is an effort to immunize the adult population of Iceland due to the COVID-19 pandemic. As of July 2021, more than 260,000 individuals had received at least one dose of COVID-19 vaccine, which was over 78% of the country's population. On November 21, 2021, 90% of the target population had been fully vaccinated, while around 1 in 5 people had received a booster on top of that; by December 9, 2021, the share of the population having received a booster shot exceeded 50%. On December 13, 2021, the country began offering Pfizer vaccinations to children aged 5–11.
COVID-19 vaccination in Sri Lanka is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, in response to the ongoing pandemic in the country. As of late July, the Sinopharm BIBP vaccine accounted for 78% of the total 13.8 million vaccines obtained by Sri Lanka to date. The United States donated over 1.5 million Moderna vaccine through COVAX.
COVID-19 vaccination in Taiwan is an ongoing immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Egypt is an ongoing immunisation campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the ongoing pandemic in the country.
COVID-19 vaccination in Ontario began in December 2020, when the first doses of the Pfizer-BioNTech COVID-19 vaccine were administered. In February 2021, shipments for both the Pfizer and Moderna vaccines increased significantly. By May 2021, over 50 percent of Ontarians had received their first dose. By the beginning of 2022, over 80 percent of Ontarians had received their first dose.